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Arrhythmogenic right ventricular cardiomyopathy type V (ARVC-5) is the 4 
most aggressive heterozygous form of ARVC. It is predominantly caused by 5 
a fully penetrant mutation (p.S358L) in the non-desmosomal gene TMEM43 6 
 endemic to Newfoundland, Canada. To date, all familial cases reported 7 
worldwide share a common ancestral haplotype. It is unknown whether the 8 
p.S358L mutation by itself causes ARVC-5 or if the disease is influenced by 9 
genetic or environmental factors.  10 
 11 
Objective 12 
To examine the phenotype, clinical course and the impact of exercise on 13 
patients with p.S358L ARVC-5 without the Newfoundland genetic 14 
background.  15 
 16 
Methods  17 
We studied 62 affected individuals and 73 non-carriers from 3 TMEM43-18 







Haplotype analysis revealed that the 3 Spanish families were unrelated to 1 
ARVC-5 patients with the Newfoundland genetic background. Two families 2 
shared 10 microsatellite markers in a 4.9 cM region surrounding TMEM43; 3 
the third family had a distinct haplotype. Affected individuals presented a 4 
38.7% incidence of SCD, higher in males. LV involvement was common with 5 
40% of mutation carriers showing LVEF<50%. Compared with non-carriers, 6 
R wave in V3 was lower (3.2±2.8 vs 7.5±3.6 mV; P<0.001) and QRS in right 7 
precordial leads wider (104.7±24.0 vs 88.2±7.7 ms;P=0.001). History of 8 
vigorous exercise showed a trend towards more ventricular arrhythmias 9 





ARVC-5 is associated with high risk of SCD and characteristic clinical and 15 
ECG features irrespective of geographical origin and genetic background. 16 
Our data suggest that, as in desmosomal ARVC, vigorous physical activity 17 
could aggravate the phenotype of TMEM43 mutation carriers. 18 
 19 





Keywords: TMEM43, arrhythmogenic right ventricular cardiomyopathy, 1 





Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a common 2 
cause of sudden cardiac death (SCD) in young adults. It is considered 3 
primarily a disease of the desmosome, as mutations in desmosomal genes 4 
have been identified in ~50% of patients who fulfil diagnostic criteria (1).  5 
 The most aggressive heterozygous form of ARVC is ARVC type V 6 
(ARVC-5). A missense mutation on chromosome 3p25, within the non-7 
desmosomal gene encoding transmembrane protein 43 (TMEM43 8 
c.1073C>T, p.S358L), was reported in 2008 as a cause of ARVC-5 in 15 9 
families from the island of Newfoundland, Canada (2,3). These families 10 
share a common ancestral haplotype, and the affected subjects present an 11 
autosomal dominant, fully penetrant, sex-influenced and high-risk form of 12 
ARVC. Later, other mutations in the same gene have been associated with 13 
ARVC-5, but p.S358L is the predominant one (4).  14 
 The p.S358L mutation leading to ARVC-5 was also identified in 15 




analysis revealed that those families shared a common ancestor with the 1 
Newfoundland affected patients (5).  2 
 To date, the TMEM43-p.S358L missense mutation responsible for 3 
ARVC-5 has only been reported once in a patient with a non-4 
Newfoundland origin (4). This single case was described in Toronto 5 
(Canada) and corresponds to a 43 year-old male from New Zealand with a 6 
confirmed de novo mutation, suggesting that a hot spot for this sequence 7 
alteration might exist at this point in TMEM43.  8 
 No descriptions of additional non-Newfoundland patients have 9 
appeared and data are lacking regarding patients with ARVC-5 without the 10 
Newfoundland genetic background. It is also currently unknown whether 11 
the p.S358L mutation itself causes ARVC-5 or if the disease expression is 12 
influenced by the genetic background or environmental factors.  13 
 In the present study, we sought to describe the phenotype and 14 






Study population 1 
Three apparently unrelated families with a high incidence of sudden cardiac 2 
death (SCD) across multiple generations were evaluated at four centres in 3 
Madrid, Valencia and Granada, Spain. This study was approved by the 4 
ethics committee of the participant centers and complies with the 5 
Declaration of Helsinki. All participants provided written informed consent. 6 
We investigated the phenotype and natural history of ARVC-5 disease 7 
caused by the p.S358L mutation in these families by comparing clinical 8 
events and test results in affected versus unaffected family members (family 9 
controls) born at a priori 50% risk, an ascertainment strategy unrelated to 10 
clinical presentation. Haplotypes from the three families were compared 11 
with those present in Newfoundland-related individuals from Denmark, 12 
Germany, North America and Newfoundland. 13 
 Subjects were considered affected if they were genetically confirmed, 14 
obligate carriers of the p.S358L mutation or had SCD ≤ 50 years (3). 15 




mutation. The remaining subjects were considered unknown and were not 1 
studied further.  2 
 To minimise the bias present in recognising cases with SCD and 3 
missing cases with minimal disease, we limited the analysis to subjects from 4 
sibships where the disease status (affected or unaffected) of ≥50% of 5 
siblings was known, as previously described (6). Clinical evaluation included 6 
a detailed medical history, physical examination, ECG and transthoracic 7 
echocardiogram.  8 
 The burden of physical activity was assessed by means of a 9 
structured telephone interview to available individuals. Participants were 10 
asked about the intensity and duration of regularly performed exercise, 11 
including leisure-related, transportation and work activities since 10 years of 12 
age. Intensity was rated according to the Multi-Ethnic Study of 13 
Atherosclerosis Typical Week Physical Activity Survey as previously 14 
described (7). Exercise duration was determined after asking the subjects 15 
between which ages and how many hours per day had they participated in 16 




intensity exercise (>70% of maximum oxygen uptake) was performed more 1 
than 50 hours per year (8).   2 
 3 
Haplotype analysis 4 
A total of 16 microsatellite markers spanning TMEM43 on chromosome 5 
3p25 were selected for haplotype analysis, which was performed in selected 6 
members from the three Spanish families and in three additional families 7 
from Newfoundland, Denmark and North America. None of the families 8 
were known to be related. The genetic distances (cM) were inferred from 9 
the deCODE genetic map. 10 
 11 
Statistical analysis 12 
Results are presented as mean (standard deviation) for continuous variables 13 
with normal distribution, as median (interquartile range) for continuous 14 
variables without normal distribution, and as number (percentage) for 15 
categorical data. For statistical analysis, Student s t-test and the Mann-16 




square test or Fisher's exact test were used for categorical variables. A two-1 
tailed P-value of <0.05 was considered to be statistically significant. All 2 
statistical analyses were performed using the SPSS package, version 20.0 3 





The three families comprised a total of 180 subjects (Figure 1). The family 2 
evaluated in Madrid (Family 1) had a total of 131 members across 7 3 
generations. The 5-generation family from Valencia had 24 members 4 
(Family 2) and the remaining 25 subjects belonged to a 5-generation family 5 
from Granada (Family 3). Considering the three families, a total of 62 6 
patients (59.7% males; mean age at last evaluation or death 39.1±17.6 7 
years) were classified as affected (30 genetically-confirmed carriers, 14 were 8 
obligate carriers and 18 untested individuals who had SCD ≤50 years of 9 
age and belonged to sibships where the disease status of ≥50% of siblings 10 
were known). The remaining subjects were either non-carriers (n=73, 56.2% 11 
males; mean age at last evaluation or death 46.1±17.6 years) or their 12 
clinical status was considered as unknown (n=45, 42.2% males; mean age at 13 
last evaluation or death 50.0±41.5 years). Subjects in the unknown group 14 
were not further analysed.  15 
 The p.S358L (c.1073C>T) TMEM43 missense mutation was initially 16 




(including >50 genes) or by exome sequencing in the probands from the 3 1 
families. No other pathogenic variants were identified in desmosomal or 2 
other cardiomyopathy-related genes. The presence of the p.S358L TMEM43 3 
mutation in probands was confirmed by PCR amplification and Sanger 4 
sequencing. Family members who agreed to undergo genetic testing were 5 
tested for the presence of the p.S358L TMEM43 mutation also by Sanger 6 
sequencing. 7 
 8 
Haplotype analysis 9 
Haplotype analysis revealed that index patients from Family 1 and 2 shared 10 
10 microsatellite markers in a 4.9 cM region surrounding TMEM43. 11 
Comparison of the haplotypes from Family 1 and 2 with those of patients 12 
with p.S358L ARVC-5 from Newfoundland, United States and Denmark 13 
showed that only 5 common markers were shared (Figure 2). Thus, the 14 
p.S358L mutation leading to ARVC-5 in Family 1 and 2 was not inherited 15 
from the same ancestor as the patients in the other regions. The haplotype 16 




Newfoundland-origin patients, and this family was considered to have a 1 
different genetic origin (Figure 2). 2 
 3 
Genotype and phenotype analysis 4 
Pedigree analysis and clinical follow-up of Family 1 revealed 36 affected 5 
subjects. A total of 15 subjects tested positive for the TMEM43-p.S358L 6 
mutation, while 11 individuals were obligate carriers and 10 had 7 
experienced SCD ≤50 years of age and belonged to sibships where the 8 
disease status of ≥50% of siblings was known. Family 2 had 12 affected 9 
subjects (5 confirmed carriers, 2 obligate carriers and 5 subjects with SCD ≤ 10 
50 years). In Family 3, there were 14 affected subjects (10 confirmed 11 
carriers, 1 obligate carrier and 3 SCD ≤ 50 years). Clinical, ECG and 12 
echocardiographic findings of the three families are summarised in Table 1 13 
and pedigrees are depicted in Figure 1.  14 
 TMEM43-affected individuals showed a 31% incidence of SCD ≤50 15 
years (n=19) and the youngest individual who suffered SCD was 22-year-16 




more prevalent among male subjects compared to female subjects (45.9% 1 
vs 8.0%; P=0.002). QRS duration was also longer in male mutation carriers 2 
compared to non-carriers (115.6±27.2 vs 94.5±15.6 ms;P=0.02). A total of 24 3 
carriers presented SCD (mean age 44.6±14.3 years). Heart failure was the 4 
cause of death in 2 mutation carriers (ages 47 and 70) and stroke in 5 
another 2 (ages 64 and 69).  6 
 Considering echocardiographic parameters, mean left ventricular 7 
ejection fraction (LVEF) was significantly lower in mutation carriers than in 8 
non-carriers at first evaluation (56.2±10.9% vs 62.1±7.0%;P<0.001), while 9 
left ventricular end diastolic volume (LVEDV) was significantly greater 10 
(106.3±40.4 vs 84.1±18.3 ml;P=0.03). LVEF was found to be <50% in 37.5% 11 
of the mutation carriers and almost 20% of affected patients presented 12 
clinical heart failure (Table 1). 13 
Regarding right ventricular echocardiographic parameters, systolic function 14 
assessed by TAPSE was found to be lower in carriers (19.1±8.4 vs 23.5±3.5 15 
mm;P=0.03) despite right ventricle (RV) size was not significantly different 16 




 Regarding ECG findings, mean QRS duration in right precordial leads 1 
was significantly wider in mutation carriers than in non-carriers (104.7±24.0 2 
vs 88.2±7.7 ms;P=0.002), and mean R in V3 was 3.2±2.8 as compared with 3 
7.5±3.6 mV in non-carriers (P<0.001) (Table 1 and Figure 3). 4 
 Shown in Figure 3 is a representative three-dimensional 5 
endomyocardial voltage map of an ARVC-5 patient who had undergone 6 
ventricular tachycardia ablation, showing extensive areas of scar in the right 7 
ventricle. Also shown are cardiac MRI from two affected patients. 8 
Additionally, Figure 4 shows the postmortem study of the heart from an 9 
ARVC-5 patient who experienced SCD, with biventricular fatty infiltration 10 
and evidence of fibrosis in the histological analysis. 11 
 12 
Physical activity in patients with ARVC-5  13 
Among the 27 mutation carriers available for exercise telephone interviews, 14 
13 (76.9% male) were considered to have a vigorous physical activity 15 
history since the age of 10, and the remaining 14 (35.7% male) were 16 




had performed daily farming and agriculture activities, including 1 
heavy carrying and lifting, for more than 10 years. One patient worked 2 
transporting heavy furniture for 7 years, another worked 15 years as a 3 
baker lifting >20 kg bags, and the remaining 2 practised sports with high 4 
dynamic demand at vigorous intensity for a mean of >50 hours per year 5 
(7).  6 
 The prevalence of ventricular tachycardia and/or ventricular 7 
fibrillation (VT/VF) was 61.5% in the vigorous physical activity group 8 
compared with 28.6% in the group with a history of less physical activity, 9 
and the difference showed a statistical trend but did not reach significance 10 
(P=0.08). As male ARVC-5 subjects are known to have a very poor 11 
prognosis with high incidence of arrhythmias, we undertook a sub-analysis 12 
by sex. We found no differences regarding VT/VF incidence in men who 13 
performed high intensity exercise (60% in males with both vigorous and 14 
non-vigorous exercise history; P=1). By contrast, vigorous exercise 15 




(66.7% vs 11.1%;P=0.054). However, exercise did not have a negative 1 




The present study provides the first clinical description of ARVC-5 in 6 
families with a non-Newfoundland-related genetic background. Our study 7 
confirms that ARVC-5 caused by the p.S358L mutation in TMEM43 is a fully 8 
penetrant arrhythmic cardiomyopathy associated with a high risk of SCD 9 
irrespective of the patients  geographical origin and genetic background. 10 
Moreover, it confirms the worse prognosis of male mutation carriers, that 11 
left ventricle (LV) structural and functional abnormalities are frequent in 12 
ARVC-5, and that ECG signs such as lower voltages in V3 (which depicts 13 
poor R wave progression [PRWP]) and prolonged QRS in right precordial 14 
leads are hallmarks of the disease. Finally, our study shows for the first time 15 
that vigorous exercise is likely to be associated with arrhythmias in ARVC-5, 16 





Phenotype of ARVC-5 in non-Newfoundland patients 1 
The observed phenotype and clinical course of the affected Spanish 2 
individuals was in concordance with previous reports of ARVC-5 patients from 3 
Newfoundland (2,3). ECG characteristics of the affected patients were 4 
prolonged QRS duration in right precordial leads, as well as PRWP, which 5 
was identified by a lower R wave voltage in V3. Interestingly we observed 6 
that a cut-off value of R amplitude <4.5mV had a sensitivity of 80.6% and a 7 
specificity of 74.1% to predict mutation carriers in our cohort. 8 
 We also observed that the LV was enlarged and dysfunctional in 9 
affected individuals as compared with non-carriers, with almost 40% of the 10 
affected subjects with a LVEF under 50% (and ventricular arrhythmia in 89% 11 
of these). In contrast, at the right ventricle (RV) only systolic function was 12 
statistically different between mutation carriers and non-carriers. Actually, in 13 
our patients, the 2010 modified Task Force criteria (9) would have established 14 
a definite diagnosis in only 37% of affected patients.  15 
These findings support a biventricular involvement with a LV predominance 16 




cardiomyopathy” is probably more appropriate for individuals harbouring a 1 
mutation in TMEM43 (10).  2 
 3 
Regarding the influence of sex on the disease, we observed a more severe 4 
phenotype among male carriers (Figure 5), as previously described in the 5 
Newfoundland cohort (2,3). This finding along with the high SCD rate 6 
observed, supports the adoption of the Newfoundland protocol to prevent 7 
SCD outside its endemic area. In that protocol, tailored management based 8 
on genetic findings is recommended including the implantation of an ICD 9 
in male mutation carriers by the age of 18 years, even in the absence of 10 
any cardiac abnormality. In female carriers, ICD is recommended only in the 11 
presence of any abnormal cardiac clinical test and, in particular, when there 12 
is an excess of premature ventricular ectopics present in 24-hour Holter 13 
ECG. The therapeutic strategy adopted in Newfoundland takes into account 14 
the gender differences observed in their ARVC-5 population and that the 15 




cohort we observed a worst clinical course among male mutation carriers 1 
and the youngest individual who suffered SCD was a 22 years-old male.  2 
The Newfoundland ICD protocol has proven to be highly effective in 3 
their population and is a major factor in prolonging survival among these 4 
patients (6). Indeed, as a result of its adoption in Newfoundland, the 5-year 5 
survival in males who has risen from 65% to 95%, and from 85% to 97% in 6 
females (6).  7 
We have adopted the Newfoundland s ICD implantation protocol in 8 
our ARVC-5 Spanish families and have been using during the last 7 years. 9 
Since the adoption of the protocol, we have not had any additional cases 10 
of SCD whereas 10 VT/VF events have been aborted during this period. 11 
 Overall, our results show that the TMEM43-p.S358L mutation causes 12 
the aggressive ARVC-5 in non-Newfoundland-related families and in 13 
different geographical regions, suggesting that the mutation effect is not 14 
influenced by additional genetic factors. Our findings should enable 15 




recognise the disease and adopt appropriate management, following the 1 
pioneering work of the Newfoundland group. 2 
 3 
Impact of physical activity in ARVC-5 4 
A history of vigorous physical activity presented a trend towards 5 
increased risk of VT/VF in our cohort. However, in the subanalysis by gender 6 
this trend was restricted to females (66.7% of VT/VF in vigorous exercise vs 7 
11.1% in non vigororous; P=0.054), and males presented a high prevalence 8 
of VT/VF episodes irrespective of the exercise burden (60% in both groups). 9 
Previous studies in desmosomal ARVC have shown a clearly increased 10 
arrhythmic risk associated with endurance exercise irrespective of sex 11 
(11,12). 12 
 While our results could be influenced by the limited number of 13 
individuals evaluated, the absence of worsening by exercise in males (who 14 
are the more severely affected) together with the finding that ECG and 15 
echocardiographic parameters are comparable in exercised and unexercised 16 
male genetic carriers suggest that genotype is a very strong contributor to a 17 
severe phenotype in ARVC-5 in males and that other factors do not seem to 18 




phenotype in female mutation carriers in whom the genotype effect on the 1 
clinical course is known to be weaker. Another factor that could be involved in 2 
these findings is hormonal. It has been described that low levels of estradiol 3 
could enhance cardiovascular events in females with ARVC (13). As regular 4 
exercise lowers estradiol levels (14), this could partly explain the mechanism 5 
of how vigorous exercise affects female ARVC5 patients.  6 
 Although, it has been previously observed that physical activity modifies 7 
cardiac structure among ARVC patients without desmosomal mutations (15), 8 
our study is the first to provide data about exercise impact on TMEM43 9 
mutation carriers.  10 
A recent study from our group using an ARVC-5 transgenic mouse 11 
model has shown that TMEM43 protein is predominantly located at nuclear 12 
membrane where it interacts with emerin and β-actin. In this model, 13 
TMEM43-S358L shows partial delocalization to the cytoplasm, reduced 14 
interaction with emerin and β-actin, and activation of GSK3β (16). As ARVC-5 15 
is a very rare disease, animal models might also be helpful in the future to 16 
elucidate potential epigenetic and environmental factors that could impact 17 
on ARVC-5 phenotype, as has been previously described for other ARVC 18 






The number of patients included in this study is limited, even taking 1 
into account that ARVC-5 is a very rare disease. Particularly, results 2 
regarding impact of physical activity on ARVC-5 phenotype should be taken 3 
with caution as they were derived from only 27 mutation carriers. 4 
Moreover, determination of physical activity performed over a large time 5 
period by telephonic interviews using questionnaires is subject to several 6 
potential bias. 7 
Lastly, there was a non-negligible number of subjects in which the clinical 8 
status was unknown. Although information from non-genotyped individuals 9 
with premature SCD were only considered when those subjects belonged 10 
to sibships where the disease status of ≥50% of siblings was known, and 11 
this methodology has already been used to characterize natural history in 12 
ARVC-5 in Newfoundland (3), we admit that this approach could also have 13 
caused an important selection bias.  14 
 15 
Conclusions 16 




high risk of SCD irrespective of the patients  geographical origin and 1 
genetic background. Our data confirm that the disease is sex-influenced, 2 
with a more severe expression in male patients, and that involvement of 3 
left ventricle is common. As in other subtypes of ARVC, vigorous physical 4 
activity seems to aggravate the phenotype of TMEM43 mutation carriers, 5 
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Figure 1. Pedigrees of the three Spanish families with the p.S358L mutation 3 
in TMEM43. A: Family 1. Madrid, B: Family 2. Valencia, C: Family 3. Granada. 4 
Red asterisk: confirmed genetic carriers, green asterisk: confirmed non-5 
carriers.  6 
SCD: Sudden cardiac death 7 
 8 
Figure 2. Haplotypes surrounding TMEM43 in p.S358L mutation carriers of 9 
three Spanish families compared with those from Newfoundland, Denmark 10 
and North America. Markers from the family from Madrid are depicted in yellow 11 
and those from the family from Granada are in green. The Newfoundland 12 
markers appear framed and those shared with the other families are 13 
underlined. Families from Madrid and Valencia only share 5 markers with 14 
the Newfoundland family whereas the family from Granada shares 6 genetic 15 
markers with the Newfoundland family. In contrast, the Danish and North 16 
American families share with the Newfoundland family 10 and 8 markers, 17 
respectively. Moreover, the latter share the 4 markers surrounding the 18 
mutation with the Newfoundland family, confirming the presence of a 19 
common ancestor.  20 
 21 
Figure 3. (A) Representative 12-lead ECG of a 55 year-old female ARVC-5 22 




(110 ms). (B) Three-dimensional voltage endomyocardial map of a 47 year-1 
old ARVC-5 male with VT episodes who underwent substrate ablation. Grey 2 
areas represent low voltage tissue (scar) along the interventricular septum 3 
and inferior wall. Brown dots represent radiofrequency applications. (C,D) 4 
CMR images of a 48 year-old ARVC5 male subject with biventricular dilatation, 5 
wall motion abnormalities and dysynchronic contraction (red arrows) LVEF 6 
35%, RVEF 46%. (E,F) CMR images of the same subject depicting severe and 7 
almost concentric intramyocardial late gadolinium enhancement (red arrows). 8 
 9 
Figure 4. Post-mortem study of the heart of an ARVC-5 TMEM43 p.S358L 10 
heterozygous carrier and victim of SCD. (A,B) Macroscopic study showing 11 
biventricular fibro-fatty infiltration, including transmural (RV), subendocardial 12 
(RV and LV) and intramyocardial (LV) localizations. (C,D) Histologic view with 13 
Masson´s trichrome staining depicting fatty infiltration (asterisks) and fibrosis 14 
(arrowheads), together with cardiomyocyte degeneration (arrows).  15 
 16 
 17 
Figure 5. Survival curve in 62 ARVC-5 affected patients according to sex. 18 
 
 






Unaffected Affected  
vs 
unaffected  
Affected males  
vs 
affected females 
Male Female Total Male Female Total 
Number of subjects (%) 37 (59.7) 25 (40.3) 62 41 (56.2) 32 (43.8) 73   
Age (years), mean (SD) 36.5 (14.9) 43.1(20.9) 39.1 (17.6) 48.6 (15.0) 43.7 (20.1) 46.1 (17.6) 0.07 0.10 
SCD (%) 20/37 (54.0) 4/25 (14.0) 24/62 (38.7) 0/41 (0) 0/32 (0) 0/73 (0) <0.001 0.03 
SCD ≤50 years (%) 17/37 (45.9) 2/25 (8.0) 19/62 (30.6) - - - - 0.002 
SCD age (SD) 41.8 (11.5) 61.0 (15.7) 44.6 (14.3) - - - - 0.004 








Male carriers  
vs 
Female Carriers 
 Male             Female             Total Male              Female             Total 
12 lead ECG 
Subjects tested 13 14 27 20 17 37   
 
 
QRS duration, ms (SD) 115.6 (27.1) 94.5 (15.5) 104.7 (24.0) 90.3 (9.9) 85.8 (7.1) 88.2 (8.9) <0.001 0.02 
V3 R voltage, mV (SD) 2.6 (2.3) 3.6 (3.2) 3.2 (2.8) 8.6 (4.1) 6.2 (2.4) 7.5 (3.6) <0.001 0.35 
Echocardiogram  
Subjects tested 14 15 29 19 14 41   
LVEF, % (SD) 53.6 (9.0) 58.7 (12.2) 56.2 (10.9) 63.3 (7.3) 60.8 (6.6) 62.1 (7.0) <0.001 0.21 
LVEDD HF, % (SD) 113.0 (18.8) 98.7 (12.6) 106.9 (17.5) 97.8 (9.5) 94.4 (10.4) 96.6 (9.6) 0.07 0.13 
LVEDV, ml (SD) 125.0 (43.6) 80.2 (12.9) 106.3 (40.4) 90.6 (15.64) 70.3 (16.62) 84.1 (18.3) 0.03 0.04         
TAPSE, mm (SD) 17.5 (8.9) 22.6 (4.6) 19.9 (7.5) 23.5 (3.0) 23.6 (4.1) 23.5 (3.5) 0.03 0.10 




4CH, four-chamber view; SCD, sudden cardiac death; SD, standard deviation; RVBD, right ventricle basal diameter; LVEF, left ventricular 
ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; TAPSE,  tricuspid annular 
























Table 2. Impact of physical activity on clinical, electrocardiographic and echocardiographic characteristics in TMEM43-





Vigorous physical activity 
 
Non-vigorous physical activity Vigorous 
vs non-
vigorous  
Vigorous PA in 
males  
vs 
vigorous PA in 
females 
Male Female Total       Male Female Total 
Number of subjects, n 
(%) 
10/13 (76.9) 3/13 (23.1) 13 5/14 (35.7) 9/14 (64.3) 14 
  
Age (years), mean (SD) 38.1 (18.6) 47.3 (9.6) 40.2 (17.1) 33.8 (14.7) 38.0 (16.9) 36.5 (15.7) 0.56 0.44 
ICD implanted, n (%) 7/10 (70.0) 3/3 (100) 10/13 (76.9) 4/5 (90.0) 3/9 (33.3) 7/14 (50.0) 0.24 0.53 
SVT/VF, n (%) 6/10 (60.0) 2/3 (66.7) 8/13 (61.5) 3/5 (60.0) 1/9 (11.1) 4/14 (28.6) 0.08 0.85 
Heart failure, n (%)  1/10 (10.0) 1/3 (33.3) 2/13 (15.4) 1/5 (20.0) 1/9 (11.1) 2/14 (14.3) 1 0.42 
12 lead ECG 
Subjects tested, n 8 3 11 4 9 13   
QRS width in ms, mean 
(SD) 
114.0 (31.7) 91.0 (12.7) 107.7 (29.2) 125.3 (7.81) 97.1 (18.1) 105.8 (21.5) 
0.85 0.27 




4CH, four-chamber view; PA: Physical activity, RVBD, right ventricle basal diameter; SVT, sustained ventricular tachycardia; VF, 
ventricular fibrillation; SD, standard deviation; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic 
diameter; LVEDV, left ventricular end-diastolic volume; TAPSE, tricuspid annular plane systolic excursion. 










Subjects tested, n 7 3 10 3 9 12   
LVEF, % (SD)     54.4 (9.5) 63.3 (6.4) 56.8 (9.4) 51.0 (9.3) 58.4 (12.7) 55.8 (11.8) 0.81  0.17 
LVEDD, mm (SD) 53.4 (11.1) 48.0 (10.6) 47.5 (7.6) 52.4 (6.3) 44.5 (7.1) 51.8 (10.7) 0.86           0.49 
LVEDV, ml (SD) 119.0 (49.3) 87.0 (10.5) 107.0 (41.2) 140.0 (32.5) 70.0 (9.9) 105.0 (44.9) 0.94           0.23 
TAPSE, mm (SD) 16.6 (10.4) 17.5 (0.7) 16.7 (9.2) 19.5 (0.7) 21.0 (9.6) 20.7 (8.5) 0.32  0.90 
RVBD 4CH, mm (SD) 42.2 (8.5) 30.0 (1.7) 37.6 (9.1) 34.0 * 32.0 (3.2) 32.4 (2.9) 0.17  0.06 
 
 
 





